Use Of Baricitinib In Patients With Moderate To Severe Coronavirus Disease 2019

Boghuma K Titanji,Monica M Farley,Ashish Mehta,Randi Connor-Schuler,Abeer Moanna,Sushma K Cribbs,Jesse O'Shea,Kathryn DeSilva, Bonnie Chan,Alex Edwards,Christina Gavegnano,Raymond F Schinazi,Vincent C Marconi

CLINICAL INFECTIOUS DISEASES（2021）

引用 150|浏览3

暂无评分

摘要

Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID- 19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.

查看译文

关键词

COVID-19, baricitinib, hyper-inflammation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要